[(E,3R)-3-hydroxy-2,2-dimethyloctadec-4-enyl] dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: [(E,3R)-3-hydroxy-2,2-dimethyloctadec-4-enyl] dihydrogen phosphate
• 化学式: C₂₀H₄₁O₅P
• 分子量: 392.5
• InChiKey: OZDAUPOECIUKMP-BMINWGARSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  26
• 可旋转键数：
  17
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  87
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• NOVEL COMPOUNDS
  申请人：AVANTI POLAR LIPIDS, INC.

  公开号：US20160024001A1

  公开（公告）日：2016-01-28

  Disclosed are compounds of the general formula I and II (as further defined herein) are useful in the production of inhibitors of sphingolipid synthesis the production of sphingolipids. Suitable sphingolipids, include, but not limited to, sphingosine and compounds incorporating sphingosine or that may use sphingosine as an intermediate or a starting material in their synthesis (including, but not limited to, sphingosine-1-P, ceramide, gangliosides and sphigomyelin). In one contemplated use, compounds of the general formula I and II are useful in the production of sphingosine. In another contemplated use, compounds of the general formula I and II are useful in the production of a sphingofugin. Methods of manufacturing each of the above compounds are also provided.

  本发明公开了一般式I和II（如下文所定义）的化合物，其在制备鞘脂合成抑制剂和鞘脂的生产中有用。适当的鞘脂包括但不限于神经酰胺和包含神经酰胺或可能在其合成中使用神经酰胺作为中间体或起始材料的化合物（包括但不限于神经酰胺-1-P，鞘醇胺，神经节苷脂和鞘磷脂）。在一种考虑中，一般式I和II的化合物在制备神经酰胺方面有用。在另一种考虑中，一般式I和II的化合物在制备神经酰胺素方面有用。还提供了制造上述每种化合物的方法。
• dhS1P AND USE OF SAME AS AN ANTICANCER THERAPEUTIC AND IMMUNOMODULATOR
  申请人：THE PENN STATE RESEARCH FOUNDATION

  公开号：US20140205669A1

  公开（公告）日：2014-07-24

  Use of dhS1P and/or PhotoImmunoNanoTherapy as a therapeutic agent is described. Administration of therapeutically effective amounts of dhS1P decrease the number of Myeloid Derived Suppressor Cells and immune suppression in cancer patients. Administration of therapeutically effective amounts of dhS1P can be used as an adjuvant to conventional cancer therapies including immunotherapies. Therapeutic results can be achieved by directly administering dhS1P and/or by indirectly increasing the amount of dhS1P at the tumor site. The therapy permits the patient's immune system to recognize and eliminate cancer cells reducing tumor size and extending patient survival.
• US20140275591A1
  申请人：——

  公开号：US20140275591A1

  公开（公告）日：2014-09-18
• US9403760B2
  申请人：——

  公开号：US9403760B2

  公开（公告）日：2016-08-02